A new article will be published. In this study 96 Post-COVID patients, 59 ME/CFS patients and healthy controls were included. The results showed significantly higher ß2 adrenergic AAB titers than the other groups. Patients with post-COVID condition showed more pathological M3 muscarinic AAb results compared to the healthy control group. Read the article here.
The international ME/CFS Symposium will take place again in Berlin on 7 and 8 May. CellTrend is a sponsor of this important event, where the current state of scientific research will be discussed and new project ideas will be developed. Online participation is free of charge upon registration (link below)! On Friday afternoon, the focus…
CellTrend was the first to describe autoantibodies against GLP-1R and has filed a patent application. This patent covers a test system for the diagnosis, prognosis, and treatment monitoring of myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS) in patients. The anti-GLP-1R antibody can only be determined by CellTrend using serum analysis.
